Clinical trial
Docetaxel in Head and Neck Cancer
NCT00261703 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00261703 |
|---|---|
| Title | Docetaxel in Head and Neck Cancer |
| Official title | Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck Cancer (LAHNC). |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Neoplasms |
| Intervention type | Drug, Other |
| Interventions | Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin + radiotherapy |
| Enrollment | 439 |
| Start date | Dec 1, 2002 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Dec 5, 2005 |
| Last update posted | May 11, 2012 |
| Countries | Portugal, Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: